Candida species in cystic fibrosis: A road less travelled

Medical Mycology

Volumn 48, Issue O1, 2010, Pages

  Chotirmall, Sanjay H ^a   Greene, Catherine M ^a   McElvaney, Noel G ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Candida; colonization; Cystic fibrosis; immune response; infection

Indexed keywords

CHITIN; COLONY STIMULATING FACTOR; COMPLEMENT RECEPTOR; DECTIN 2; FLUCONAZOLE; GALECTIN 3; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; LECTIN RECEPTOR; MANNAN; MANNAN BINDING LECTIN; MESSENGER RNA; POLYSACCHARIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1;

AIRBORNE INFECTION; BALANITIS; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CELLULAR IMMUNITY; CYSTIC FIBROSIS; DEVICE INFECTION; FUNGUS GROWTH; GENITAL CANDIDIASIS; HUMORAL IMMUNITY; INNATE IMMUNITY; INVASIVE CANDIDIASIS; MOUTH EXAMINATION; MOUTH HYGIENE; NONHUMAN; PRURITUS; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; THRUSH; TRANSPLANTATION; VASCULAR ACCESS DEVICE;

CANDIDA; CANDIDIASIS; CYSTIC FIBROSIS; HUMANS; SPECIES SPECIFICITY; VIRULENCE;

CANDIDA;

EID: 78649918852     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.503320     Document Type: Review

References (103)

1. Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005; 43: 284-292.
2. Denning D. Fortnightly review: management of genital candidiasis. BMJ 1995; 10: 1241-1244.
3. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003; 67: 400-428.
4. Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-421.
5. Horn DL, Ostrosky-Zeichner L, Morris MI, et al. Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. Eur J Clin Microbiol Infect Dis 2010; 29: 223-229.
6. Gullo A. Invasive fungal infections: the challenge continues. Drugs 2009; 69(Suppl. 1): 65-73.
7. Sahand IH, Moragues MD, Eraso E, et al. Supplementation of CHRO-Magar Candida medium with Pal's medium for rapid identif cation of Candida dubliniensis. J Clin Microbiol 2005; 43: 5768-5770.
8. Valenza G, Tappe D, Turnwald D, et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cysticf brosis. J Cyst Fibros 2008; 7: 123-127.
9. Kerem E, Conway S, Elborn S, Heijerman H. Standards of care for patients with cysticf brosis: a European consensus. J Cyst Fibros 2005; 4: 7-26.
10. Pihet M, Carrere J, Cimon B, et al. Occurrence and relevance off lamentous fungi in respiratory secretions of patients with cysticf brosis - a review. Med Mycol 2009; 47: 387-397.
11. Bakare N, Rickerts V, Bargon J, Just-Nubling G. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cysticf brosis. Mycoses 2003; 46: 19-23.
12. Bauernfeind A, Bertele RM, Harms K, et al. Qualitative and quantitative microbiological analysis of sputa of 102 patients with cysticf brosis. Infection 1987; 15: 270-277.
13. Blaschke-Hellmessen R, Spitzer H, Paul KD, Hoffmann C. [Myco-logical surveillance of children with cysticf brosis]. Mycoses 1991; 34 (Suppl. 1): 43-47. [In German]
14. Muller J, Remus N, Harms KH. Mycoserological study of the treatment of paediatric cysticf brosis patients with Saccharomyces bou-lardii Saccharomyces cerevisiae Hansen CBS 5926. Mycoses 1995; 38: 119-123.
15. Cimon B CJ, Chazalette JP, Ginies JL, Chabasse D, Bouchara JP. Bronchopulmonary mycoses in cysticf brosis. Results of af ve-year longitudinal study. J Mycol Med 2000; 10: 128-135.
16. Akpan A, Morgan R. Oral candidiasis. Postgrad Med J 2002; 78: 455-459.
17. Webb AK, Woolnough E. Candida albicans infection in adults with cysticf brosis. J R Soc Med 2006; 99(Suppl. 46): 13-16.
18. Sawyer SM, Bowes G, Phelan PD. Vulvovaginal candidiasis in young women with cysticf brosis. BMJ 1994; 308: 1609.
19. Lyon A, Gunn E, Haworth CS, Bilton D. Is genital Candida infection a signif cant problem for adults with cysticf brosis. J Cyst Fibros 2004; 3: S99.
20. Woolnough EM, Dodd ME, Jones A, Webb AK. Is candidiasis a problem in adults with cysticf brosis? A prospective study. Thorax 2004; 59: S78.
21. Nurbhai M, Grimshaw J, Watson M, et al. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vul-vovaginal candidiasis (thrush). Cochrane Database Syst Rev 2007; 4: CD002845.
22. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientif c Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745-755.
23. Helmi M, Love RB, Welter D, Cornwell RD, Meyer KC. Aspergillus infection in lung transplant recipients with cysticf brosis: risk factors and outcomes comparison to other types of transplant recipients. Chest 2003; 123: 800-808.
24. Schaenman JM, Rosso F, Austin JM, et al. Trends in invasive disease due to Candida species following heart and lung transplantation. Transpl Infect Dis 2009; 11: 112-121.
25. Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000; 70: 112-116.
26. Bonacorsi SP, Munck A, Gerardin M, et al. In situ management and molecular analysis of candidaemia related to a totally implant-able vascular access in a cysticf brosis patient. J Infect 1996; 33: 49-51.
27. Horn CK, Conway SP. Candidaemia: risk factors in patients with cysticf brosis who have totally implantable venous access systems. J Infect 1993; 26: 127-132.
28. Munck A, Malbezin S, Bloch J, et al. Follow-up of 452 totally im-plantable vascular devices in cysticf brosis patients. Eur Respir J 2004; 23: 430-434.
29. Hassan T, Chotirmall SH, Low TB, et al. Thrombolysis for indwelling catheter related thrombosis and superior vena cava obstruction in cysticf brosis: a case series. Ir J Med Sci 2010; Jun 19 [Epub ahead of print].
30. Douglas LJ. Medical importance of biof lms in Candida infections. Rev Iberoam Micol 2002; 19: 139-143.
31. Muthig M, Hebestreit A, Ziegler U, Seidler M, Muller FM. Persistence of Candida species in the respiratory tract of cysticf brosis patients. Med Mycol 2009; 31: 1-8.
32. Chotirmall SH, O'Donoghue E, Bennett K, et al. Sputum Candida albicans presages FEV1 decline and hospitalized exacerbations in cysticf brosis. Chest 2010; May 14 [Epub ahead of print].
33. Navarro J, Rainisio M, Harms HK, et al. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 2001; 18: 298-305.
34. SulliVan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 1995; 141: 1507-1521.
35. Polacheck I, Strahilevitz J, SulliVan D, et al. Recovery of Candida dubliniensis from non-human immunodef ciency virus-infected patients in Israel. J Clin Microbiol 2000; 38: 170-174.
36. Peltroche-Llacsahuanga H, Dohmen H, Haase G. Recovery of Candida dubliniensis from sputum of cysticf brosis patients. Mycoses 2002; 45: 15-18.
37. Asmundsdottir LR, Erlendsdottir H, Agnarsson BA, Gottfredsson M. The importance of strain variation in virulence of Candida dubliniensis and Candida albicans : results of a blinded histopatho-logical study of invasive candidiasis. Clin Microbiol Infect 2009; 15: 576-585.
38. Hazen KC, Wu JG, Masuoka J. Comparison of the hydrophobic properties of Candida albicans and Candida dubliniensis. Infect Immun 2001; 69: 779-786.
39. Costerton JW, Stewart PS, Greenberg EP. Bacterial biof lms: a common cause of persistent infections. Science 1999; 284: 1318-1322.
40. Hogan DA. Talking to themselves: autoregulation and quorum sensing in fungi. Eukaryot Cell 2006; 5: 613-619.
41. Williams P. Quorum sensing, communication and cross-kingdom signaling in the bacterial world. Microbiology 2007; 153: 3923-3938.
42. Hogan DA, Kolter R. Pseudomonas-Candida interactions: an ecological role for virulence factors. Science 2002; 296: 2229-2232.
43. Joint I, Tait K, Callow ME, et al. Cell-to-cell communication across the prokaryote-eukaryote boundary. Science 2002; 298: 1207.
44. Hughes WT, Kim HK. Mycof ora in cysticf brosis: some ecologic aspects of Pseudomonas aeruginosa and Candida albicans. Myco-pathol Mycol Appl 1973; 50: 261-269.
45. Williams P, Camara M. Quorum sensing and environmental adaptation in Pseudomonas aeruginosa : A tale of regulatory networks and multifunctional signal molecules. Curr Opin Microbiol 2009; 12: 182-191.
46. Lo HJ, Kohler JR, DiDomenico B, et al. Nonf lamentous C. albicans mutants are avirulent. Cell 1997; 90: 939-949.
47. Hendrickson EL, Plotnikova J, Mahajan-Miklos S, Rahme LG, Ausubel FM. Differential roles of the Pseudomonas aeruginosa PA14 rpoN gene in pathogenicity in plants, nematodes, insects, and mice. J Bacteriol 2001; 183: 7126-7134.
48. Hornby JM, Jensen EC, Lisec AD, et al. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 2001; 67: 2982-2992.
49. Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL. Inhibition of Candida albicans biof lm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 2002; 68: 5459-5463.
50. Cugini C, Calfee MW, Farrow JM, et al. Farnesol, a common sesqui-terpene, inhibits PQS production in Pseudomonas aeruginosa. Mol Microbiol 2007; 65: 896-906.
51. McAlester G, O'Gara F, Morrissey JP. Signal-mediated interactions between Pseudomonas aeruginosa and Candida albicans. J Med Microbiol 2008; 57: 563-569.
52. Dudler R, Eberl L. Interactions between bacteria and eukaryotes via small molecules. Curr Opin Biotechnol 2006; 17: 268-273.
53. Kobayashi H, Kobayashi O, Kawai S. Pathogenesis and clinical manifestations of chronic colonization by Pseudomonas aeruginosa and its biof lms in the airway tract. J Infect Chemother 2009; 15: 125-142.
54. Jenkinson HF, Douglas JL. Candida interactions with bacterial bio-f lms. In: Brogden KA, Guthmiller JM, eds. Polymicrobial Diseases, Washington DC: ASM Press, 2002.
55. Rickard AH, Gilbert P, High NJ, Kolenbrander PE, Handley PS. Bacterial coaggregation: an integral process in the development of multi-species biof lms. Trends Microbiol 2003; 11: 94-100.
56. El-Azizi MA, Starks SE, Khardori N. Interactions of Candida al-bicans with other Candida spp. and bacteria in the biof lms. J Appl Microbiol 2004; 96: 1067-1073.
57. Tawara Y, Honma K, Naito Y. Methicillin-resistant Staphylococcus aureus and Candida albicans on denture surfaces. Bull Tokyo Dent Coll 1996; 37: 119-128.
58. Adam B, Baillie GS, Douglas LJ. Mixed species biof lms of Candida albicans and Staphylococcus epidermidis. J Med Microbiol 2002; 51: 344-349.
59. Baena-Monroy T, Moreno-Maldonado V, Franco-Martinez F, et al. Candida albicans, Staphylococcus aureus and Streptococcus mutans colonization in patients wearing dental prosthesis. Med Oral Patol Oral Cir Bucal 2005; 10(Suppl. 1):E27-39.
60. Carlson E. Effect of strain of Staphylococcus aureus on synergism with Candida albicans resulting in mouse mortality and morbidity. Infect Immun 1983; 42: 285-292.
61. Carlson E. Enhancement by Candida albicans of Staphylococ-cus aureus, Serratia marcescens, and Streptococcus faecalis in the establishment of infection in mice. Infect Immun, 1983, 39, 193-197.
62. Jabra-Rizk MA, Meiller TF, James CE, Shirtliff ME. Effect of farne-sol on Staphylococcus aureus biof lm formation and antimicrobial susceptibility. Antimicrob Agents Chemother 2006; 50: 1463-1469.
63. Levison ME, Pitsakis PG. Susceptibility to experimental Candida albicans urinary tract infection in the rat. J Infect Dis 1987; 155: 841-846.
64. Kennedy MJ, Volz PA. Effect of various antibiotics on gastrointestinal colonization and dissemination by Candida albicans. Sabourau-dia 1985; 23: 265-273.
65. Holmes AR, Cannon RD, Jenkinson HF. Interactions of Candida albicans with bacteria and salivary molecules in oral biof lms. J Ind Microbiol 1995; 15: 208-213.
66. O'SulliVan JM, Jenkinson HF, Cannon RD. Adhesion of Candida albicans to oral streptococci is promoted by selective adsorption of salivary proteins to the streptococcal cell surface. Microbiology 2000; 146: 41-48.
67. Cannon RD, Chaff n WL. Colonization is a crucial factor in oral can-didiasis. J Dent Educ 2001; 65: 785-787.
68. Holmes AR, Van der Wielen P, Cannon RD, Ruske D, Dawes P. Candida albicans binds to saliva proteins selectively adsorbed to silicone. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 488-494.
69. Basson NJ. Competition for glucose between Candida albicans and oral bacteria grown in mixed culture in a chemostat. J Med Microbiol 2000; 49: 969-975.
70. Lussier M, Sdicu AM, Shahinian S, Bussey H. The Candida albican-sKRE9 gene is required for cell wall beta-1, 6-glucan synthesis and is essential for growth on glucose. Proc Natl Acad Sci USA 1998; 95: 9825-9830.
71. Buurman ET, Westwater C, Hube B, et al. Molecular analysis of CaMnt1p, a mannosyl transferase important for adhesion and virulence of Candida albicans. Proc Natl Acad Sci USA 1998; 95: 7670-7675.
72. Bulawa CE, Miller DW, Henry LK, Becker JM. Attenuated virulence of chitin-def cient mutants of Candida albicans. Proc Natl Acad Sci USA 1995; 92: 10570-10574.
73. Chauhan N, Li, D, Singh, P, Calderone, R, Kruppa, M. The cell wall of Candida spp. In: Calderone RA (ed.), Candida and Candidiasis. Washington, DC: ASM Press; 2002.
74. Masuoka J. Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges. Clin Microbiol Rev 2004; 17: 281-310.
75. Timpel C, Strahl-Bolsinger S, Ziegelbauer K, Ernst JF. Multiple functions of Pmt1p-mediated protein O-mannosylation in the fungal pathogen Candida albicans. J Biol Chem 1998; 273: 20837-20846.
76. Csank C, Schroppel K, Leberer E, et al. Roles of the Candida albi-cans mitogen-activated protein kinase homolog, Cek1p, in hyphal development and systemic candidiasis. Infect Immun 1998; 66: 2713-2721.
77. Cutler JE. N-glycosylation of yeast, with emphasis on Candida albi-cans. Med Mycol 2001; 39(Suppl. 1): 75-86.
78. Ernst JF, Prill SK. O-glycosylation. Med Mycol 2001; 39(Suppl. 1): 67-74.
79. Greene CM, McElvaney NG. Toll-like receptor expression and function in airway epithelial cells. Arch Immunol Ther Exp Warsz 2005; 53: 418-427.
80. Greene CM, Branagan P, McElvaney NG. Toll-like receptors as therapeutic targets in cysticf brosis. Expert Opin Ther Targets 2008; 12: 1481-1495.
81. Latz E, Schoenemeyer A, Visintin A, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004; 5: 190-198.
82. Greene CM, Carroll TP, Smith SG, et al. TLR-induced inf ammation in cysticf brosis and non-cysticf brosis airway epithelial cells. J Immunol 2005; 174: 1638-1646.
83. Platz J, Beisswenger C, Dalpke A, et al. Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol 2004; 173: 1219-1223.
84. Claeys S, Van Hoecke H, Holtappels G, et al. Nasal polyps in patients with and without cysticf brosis: a differentiation by innate markers and inf ammatory mediators. Clin Exp Allergy 2005; 35: 467-472.
85. Muir A, Soong G, Sokol S, et al. Toll-like receptors in normal and cysticf brosis airway epithelial cells. Am J Respir Cell Mol Biol 2004; 30: 777-783.
86. Hauber HP, Tulic MK, Tsicopoulos A, et al. Toll-like receptors 4 and 2 expression in the bronchial mucosa of patients with cysticf brosis. Can Respir J 2005; 12: 13-18.
87. John G, Yildirim AO, Rubin BK, Gruenert DC, Henke MO. TLR-4-mediated innate immunity is reduced in cysticf brosis airway cells. Am J Respir Cell Mol Biol 2010; 42: 424-431.
88. Monick MM, Yarovinsky TO, Powers LS, et al. Respiratory syncy-tial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem 2003; 278: 53035-53044.
89. Koller B, Kappler M, Latzin P, et al. TLR expression on neutrophils at the pulmonary site of infection: TLR1/TLR2-mediated up-regula-tion of TLR5 expression in cysticf brosis lung disease. J Immunol 2008; 181: 2753-2763.
90. Petit-Bertron AF, Tabary O, Corvol H, et al. Circulating and airway neutrophils in cysticf brosis display different TLR expression and responsiveness to interleukin-10. Cytokine 2008; 41: 54-60.
91. Epelman S, Berenger B, Stack D, et al. Microbial products activate monocytic cells through detergent-resistant membrane microdo-mains. Am J Respir Cell Mol Biol 2008; 39: 657-665.
92. Del Fresno C, Gomez-Pina V, Lores V, et al. Monocytes from cysticf brosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism. PLoS One 2008; 3: e2667.
93. Jaresova I, Rozkova D, Spisek R, et al. Kinetics of Toll-like recep-tor-4 splice variants expression in lipopolysaccharide-stimulated antigen presenting cells of healthy donors and patients with cysticf brosis. Microbes Infect 2007; 9: 1359-1367.
94. Mencacci A, Cenci E, Del Sero G, et al. IL-10 is required for development of protective Th1 responses in IL-12-def cient mice upon Candida albicans infection. J Immunol 1998; 161: 6228-6237.
95. Vazquez-Torres A, Jones-Carson J, Wagner RD, Warner T, Balish E. Early resistance of interleukin-10 knockout mice to acute systemic candidiasis. Infect Immun 1999; 67: 670-674.
96. Lavigne LM, Schopf LR, Chung CL, Maylor R, Sypek JP. The role of recombinant murine IL-12 and IFN-gamma in the pathogenesis of a murine systemic Candida albicans infection. J Immunol 1998; 160: 284-292.
97. Allard JB, Rinaldi L, Wargo MJ, et al. Th2 allergic immune response to inhaled fungal antigens is modulated by TLR-4-independent bacterial products. Eur J Immunol 2009; 39: 776-788.
98. Roilides E, Holmes A, Blake C, Pizzo PA, Walsh TJ. Effects of granulocyte colony-stimulating factor and interferon-gamma on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species. J Leukoc Biol 1995; 57: 651-656.
99. Gaviria JM, Van Burik JA, Dale DC, Root RK, Liles WC. Modulation of neutrophil-mediated activity against the pseudohyphal form of Candida albicans by granulocyte colony-stimulating factor (G-CSF) administered in vivo. J Infect Dis 1999; 179 : 1301-1304.
100. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inf ammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 2003; 197: 1107-1117.
101. Przyklenk B, Bauernfeind A, Horl G, Emminger G. Serologic response to Candida albicans and Aspergillus fumigatus in cysticf brosis. Infection 1987; 15: 308-310.
102. Maiz L, Cuevas M, Quirce S, et al. Serologic IgE immune responses against Aspergillus fumigatus and Candida albicans in patients with cysticf brosis. Chest 2002; 121: 782-788.
103. Maiz L, Cuevas M, Lamas A, et al. [Aspergillus fumigatus and Candida albicans in cysticf brosis: clinical signif cance and specif c immune response involving serum immunoglobulins G, A, and M]. Arch Bronconeumol 2008; 44: 146-151.